Literature DB >> 7491819

Antibody and cytotoxic T-lymphocyte responses to a single liposome-associated peptide antigen.

W I White1, D R Cassatt, J Madsen, S J Burke, R M Woods, N M Wassef, C R Alving, S Koenig.   

Abstract

The development of peptide-based vaccines that elicit antibody (Ab) and cellular immune responses has been hampered by the lack of highly immunogenic formulations. In this study, we compared the induction of Ab and cytotoxic T-lymphocyte (CTL) responses to a peptide derived from the V3 loop of HIV-1 gp120 (P18 and its cysteine-glycine derivative (CG-P18)) when incorporated into liposomes with lipid A (LA) or mixed with aluminum hydroxide. P18-specific CTL were only observed with liposomes with LA. P18-specific Ab responses were found with liposomes containing CG-P18 but not P18. Increased surface expression of the former, resulted in enhancement of the Ab response without loss of CTL induction. Thus, the manner in which a peptide is localized can influence the outcome of the response induced by highly immunogenic liposome formulations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7491819     DOI: 10.1016/0264-410x(94)00058-u

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

Review 1.  Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens.

Authors:  Douglas S Watson; Aaron N Endsley; Leaf Huang
Journal:  Vaccine       Date:  2012-02-02       Impact factor: 3.641

2.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

3.  Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo.

Authors:  J D Ballard; R J Collier; M N Starnbach
Journal:  Proc Natl Acad Sci U S A       Date:  1996-10-29       Impact factor: 11.205

4.  Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen.

Authors:  R L Richards; M Rao; N M Wassef; G M Glenn; S W Rothwell; C R Alving
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

5.  Brucella abortus conjugated with a peptide derived from the V3 loop of human immunodeficiency virus (HIV) type 1 induces HIV-specific cytotoxic T-cell responses in normal and in CD4+ cell-depleted BALB/c mice.

Authors:  C Lapham; B Golding; J Inman; R Blackburn; J Manischewitz; P Highet; H Golding
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

Review 6.  Modulating the immune system through nanotechnology.

Authors:  Tamara G Dacoba; Ana Olivera; Dolores Torres; José Crecente-Campo; María José Alonso
Journal:  Semin Immunol       Date:  2017-10-09       Impact factor: 11.130

7.  Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin.

Authors:  J D Ballard; A M Doling; K Beauregard; R J Collier; M N Starnbach
Journal:  Infect Immun       Date:  1998-02       Impact factor: 3.441

Review 8.  Army Liposome Formulation (ALF) family of vaccine adjuvants.

Authors:  Carl R Alving; Kristina K Peachman; Gary R Matyas; Mangala Rao; Zoltan Beck
Journal:  Expert Rev Vaccines       Date:  2020-03-31       Impact factor: 5.217

9.  Induction of immune responses in mice and monkeys to Ebola virus after immunization with liposome-encapsulated irradiated Ebola virus: protection in mice requires CD4(+) T cells.

Authors:  Mangala Rao; Mike Bray; Carl R Alving; Peter Jahrling; Gary R Matyas
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

10.  Role of lipid structure in the humoral immune response in mice to covalent lipid-peptides from the membrane proximal region of HIV-1 gp41.

Authors:  Douglas S Watson; Francis C Szoka
Journal:  Vaccine       Date:  2009-06-09       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.